INTRODUCTION Triple anticoagulation therapy (TT), comprising dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC), is essential in atrial fibrillation (AF) patients after percutaneous coronary intervention (PCI), but it increases the bleeding risk. AIM To assess TT models, in- and out-hospital bleeding and thromboembolic complications, and TT alterations. MATERIAL AND METHODS Dur...

OBJECTIVES The present study was conducted to determine the safety of the transcatheter closure of a patent foramen ovale (PFO) in patients with cryptogenic cerebral ischemia and the midterm follow-up of recurrent thromboembolic events after interventional PFO closure. BACKGROUND Current therapeutic options for stroke prevention in patients with PFO and a history of thromboembolic events incl...

bleeding risks. In this issue of the Journal, Sambola et al12 evaluate the efficacy and safety of TT in AF patients undergoing PCI compared with those of DAPT. They extracted data from a prospective multicenter registry that enrolled 585 AF patients undergoing PCI. The authors separately analyzed the results according to CHA2DS2-VASc score: CHA2DS2-VASc=1, 26.8% vs. CHA2DS2-VASc ≥2, 73.2%) In t...

Atrial fibrillation may be considered by some to be innocuous; however, the impact of atrial fibrillation can be substantial. Thromboembolic events and strokes are the number one cause of mortality and morbidity. For patients who do not respond to medical therapy for rate and rhythm control or are unable to take medication to decrease the risk of a stroke or thromboembolic event, the Maze proce...

Chronic thromboembolic pulmonary hypertension (CTEPH) is considered to be an extreme variant of pulmonary thromboembolism. The underlying mechanisms for the failure of thrombus resolution are still unclear. In looking for inherited thrombophilia, an association with a lupus anticoagulant has been described repeatedly, and single cases of anticoagulant deficiencies (ie, antithrombin [AT], protei...

Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of recurrence. Population pharmacokinetics, pharmacokinetics-pharmacodynamics (anti-FXa activity), and exposure-response (binary bleeding and thromboembolic endpoints) of apixaban in VTE treatment subjects were characterized using data from phase I-III studies. Apixaban pharmacokinetics were adequately characteriz...

Venous thromboembolic event after traumatic brain injury represents a unique clinical challenge. Physicians must balance appropriate timing of chemoprophylaxis with risk of increased cerebral hemorrhage. Despite an increase in the literature since the 1990s, there are clear disparities in treatment strategies. This review discusses the prominent studies and subsequent findings regarding the top...